AMZN 1.81TLN 13.24UBER 1.675ATZ.TO 2.22NOW 1.46NVDA 5.8PPL.TO 0.475ARE.TO -1.17
Teva Pharmaceutical (TEVA)

NYSE:TEVA

Teva Pharmaceutical (TEVA)

39.65
+0.12 (0.30%)
as of Oct 5, 2026, 7:59:59 pm Market Open.
71 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
PAST TOP PICK

Teva Pharmaceutical(TEVA)

Aug 16, 2002
(Was a top pick on June 21. Up 7.1%) Good long term story.
Photo of Brad WillockBrad WillockUnlock Rating
$68.39

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Teva Pharmaceutical(TEVA)

Apr 19, 2002
Over 50 new drugs waiting approval. Cheap.
Photo of Brad WillockBrad WillockUnlock Rating
$57.38

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Teva Pharmaceutical(TEVA)

Apr 05, 2002
Global. Good acquisitions. Because it is based in Israel, price has dropped inordinately.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$55.10

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Teva Pharmaceutical(TEVA)

Mar 15, 2002
World leader in generic drugs.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$57.16

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Teva Pharmaceutical(TEVA)

Jul 18, 2001
(Was a top pick on Jan 25/01 up 11%) Still likes, but may be fully valued now.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$64.35

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Teva Pharmaceutical(TEVA)

May 25, 2001
(Was a top pick on Aug 3/00 up 1.3%) Still likes and still buying.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$58.00

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Teva Pharmaceutical(TEVA)

Feb 22, 2001
Likes the generic drug sector as patent expirations are coming. Global. Good cash flow
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$58.50

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Teva Pharmaceutical(TEVA)

Jan 25, 2001
World's largest generic drug company. Good distribution. Patents are going off now so generics are prospering.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$57.25

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
BUY

Teva Pharmaceutical(TEVA)

Dec 15, 2000
Likes the generic drug space. Govts will be pressured for lower health costs. Prefers this over Biovale
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$66.94

Stock price when the opinion was issued

$39.55

As of Oct 05, 2026. Market Open.

biotechnologypharmaceutical
Showing 271 to 279 of 279 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

LNC 0.9$41.2
HPQ -0.74$31.38
MTY.TO -0.12$30.94
ENB.TO 0.23$65.77
T.TO -0.265$11.205

Today's Top Picks

AMZN 1.81$253.33
TLN 13.24$334.01
UBER 1.675$69.785
ATZ.TO 2.22$124.88
NOW 1.46$135.84

Popular Articles

Latest Sell Signals

BNS.TO -0.75$129.18
MSFT 10.47$528
LULU -2.18$92.28
BCE.TO -0.14$28.03
POET -0.01$7.78

Most Recent Experts

Mike Vinokur, CFA, CMT, and CFP

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Bruce Murray

Bruce Murray

The Murray Wealth Group

Dennis Mitchell, CFA

Dennis Mitchell, CFA

Sentry Select Capital Corp

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like